BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

The American Association for Cancer Research inaugurated Elaine Mardis as president for 2019-20. She is the co-executive director of the Institute for Genomics Medicine at Nationwide Children’s Hospital and a professor of pediatrics at Ohio...
BioCentury | Mar 22, 2019
Financial News

CanSino could get $598M valuation in Hong Kong IPO

By Hongjiang Li, Staff Writer CanSino would be valued at HK$4.7 billion (US$597.6 million) if the prerevenue vaccine company prices its Hong Kong IPO at the midpoint of the range it proposed Monday. CanSino Biologics...
BioCentury | Oct 25, 2018
Translation in Brief

Big debuts for big genomics

BGI Genomics Co. Ltd. (SZSE:300676) and UK Biobank Ltd. each made a splash this month with papers showcasing the wealth of information captured by their genomic data troves. Though the studies differed in design, technical...
BioCentury | Oct 11, 2018
Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
BioCentury | Sep 21, 2018
Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of...
BioCentury | Jul 20, 2018
Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on July 17 proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. CanSino said in its prospectus...
BioCentury | Jul 17, 2018
Financial News

CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on Tuesday proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. The news comes as multiple media...
Items per page:
1 - 10 of 316